Pipeline

June 18, 2018
Company Drug/Device Medical Condition Status
Alnylam lumasiran Primary Hyperoxaluria Type 1 (PH1) Phase I trial initiated enrolling 25 patients with PH1
Cynata Therapeutics CYP-001 steroid-resistant acute graft-versus-host disease (GvHD) Phase I trial initiated enrolling 8 patients with steroid-resistant acute GvHD
Vizuri Health Sciences VZU00025 osteoarthritis Phase II trial initiated
NeuroRx NRX-101 suicidal bipolar depression Phase IIb/III trial initiated enrolling 12 patients
Allergan atogepant episodic migraine pain Phase IIb/III trial initiated enrolling 795 patients
icotec AG BlackArmor Carbon/PEEK Interbody Cages adults and children with hemophilia A without factor VIII inhibitors 510(k) Clearance granted by the FDA
Gold Standard Diagnostics Borrelia burgdorferi IgG/IgM ELISA assay Lyme disease bacteria 510(k) clearance granted by the FDA
AbbVie and Roche Venclexta in combination with Rituxan (rituximab) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) Approval granted by the FDA
Genentech Rituxan (rituximab) moderate to severe pemphigus vulgaris (PV) Approval granted by the FDA
Fujirebio Diagnostics Lumipulse G B•R•A•H•M•S PCT Assay bacterial infections Clearance granted by the FDA
DyAnsys Drug Relief reduce the symptoms of opioid withdrawal without narcotics Clearance granted by the FDA
Arcus Biosciences AB928 breast and gynecologic malignancies Clearance granted by the FDA
Nordic Nanovector Betalutin relapsed or refractory follicular lymphoma (FL) Fast Track Designation granted by the FDA
Ironwood Pharma olinciguat (IW-1701) sickle cell disease Orphan Drug Designation granted by the FDA
AMO Pharma AMO-04 Rett Syndrome Orphan Drug Designation granted by the FDA
Samus Therapeutics PU-H71 myelofibrosis Orphan Drug Designation granted by the FDA

Upcoming Events

Featured Products

Featured Stories

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here